Jazz Pharmaceuticals to pay $20 million in penalties and compensation

Jazz Pharmaceuticals will pay $20 million in penalties and victim compensation to resolve criminal and civil investigations into illegal marketing by its Orphan Medical wholly owned subsidiary. The US Attorney for New York's Eastern District says Orphan pled guilty to felony misbranding for illegal promotion of Xyrem for unapproved uses.

You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory